Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

Blockbusters look set to grow

Posted 25 November 2021 AM

Three companies are looking to expand the market for their medications on the PBS, seeking additional indications in the March PBAC meeting, with blockbuster cancer drugs Opdivo and Keytruda leading the charge.

BMS is seeking to add a new indication for Opdivo, seeking to have it listed for "second-line squamous cell oesophageal carcinoma that have failed treatment with a fluoropyrimidine and platinum containing treatment regimen".

MSD has applied to expand the indications for blockbuster Keytruda, currently used for advanced renal cell carcinoma, to include advanced clear cell variant renal cell carcinoma.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.